TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05180955

Intervention type: OTHER
Group type: OTHER
Intervention: Digital drainage system
Description: In the intervention group; chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data, the tube will not be clamped.

Intervention type: OTHER
Group type: OTHER
Intervention: Digital drainage system + clamping trial
Description: In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
Study: NCT04728555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Game about radiotherapy
Description: A digital pedagogical game about radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Game about radiotherapy
Description: A digital pedagogical game about radiotherapy
Study: NCT04504149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD
Description: A primary care-based shared decision making intervention
Study: NCT04565899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice facilitation implementation intervention
Description: 6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
Study: NCT04585620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinum Toxin A
Description: Series of subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Series of subcutaneous injections
Study: NCT04982172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
Study: NCT05572385

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CIAT + Conventional neurorehabilitative therapy
Description: CIAT = Constrained induced aphasia therapy
Study: NCT06479330

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk Chocolate
Description: Acute intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk Chocolate
Description: Acute intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk Chocolate
Description: Acute intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk Chocolate
Description: Acute intake
Study: NCT05005689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride mouthwash (0.05%; 225ppm).
Description: Mouthwash

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tooth Mousse Plus
Description: Tooth Mousse
Study: NCT05556265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05935995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microscopy confocal (Histolog Scanner)
Description: Surgical margins of tumor samples will be examined by conventional histopathology (H\&E) and confocal microscopy (Histolog® scanner, SamanTree Medical, Switzerland).~Depending on the histopathological result obtained between the two methods, the patient may benefit directly from early surgery if the experimental result confirms the presence of positive margins (excluding the learning curve).~A learning curve will be established over the first fifteen surgeries, enabling surgical teams to gain experience and systematize specimen flattening. This learning curve will also enable reference images to be produced. The procedure will be carried out by the surgeon and the pathologist in the operating room during this phase.
Study: NCT05096572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM Stimulation
Description: Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM Stimulation
Description: Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM Stimulation
Description: Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSA Stimulation
Description: Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSA Stimulation
Description: Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSA Stimulation
Description: Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM+PSA Stimulation
Description: Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM+PSA Stimulation
Description: Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM+PSA Stimulation
Description: Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.
Study: NCT06479330

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk Chocolate
Description: Acute intake
Study: NCT05057572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: - Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP\>90, HR \>55.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: * Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: * Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)
Study: NCT05313802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study: NCT05989776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational brochure for patients and brief training for oncologists
Description: For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
Study: NCT05833828

Intervention type: PROCEDURE
Intervention: on-pump surgery
Description: the surgery will be performed on-pump

Intervention type: PROCEDURE
Intervention: off-pump surgery
Description: the surgery will be performed off-pump
Study: NCT06264674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5993 200/6/12.5 μg pMDI HFA-152a
Description: Pressurised Metered Dose Inhaler-2 inhalations twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a
Description: Pressurised Metered Dose Inhaler-2 inhalations twice daily
Study: NCT06533631

Intervention type: DEVICE
Intervention: Portable low-field MRI (pMRI)
Description: Participants will receive a pMRI during the study visit.

Intervention type: DEVICE
Intervention: 3T MRI
Description: Gold standard MRI for WMH. Participants will receive a 3T MRI during the study visit.
Study: NCT06081959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: IV infusion on day 1 and Day 15 of each 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: 1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
Study: NCT05375084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398 with nivolumab
Description: BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398 with nivolumab
Description: BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398 with nivolumab
Description: BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398 with nivolumab
Description: BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)
Study: NCT05366010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillation and Lung Expansion (OLE) therapy
Description: Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
Study: NCT05610800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 milligram (mg) Injection
Description: Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke \>10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine patch
Description: Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke \>10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
Study: NCT05717803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Description: The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
Study: NCT05467670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX148
Description: A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
Study: NCT05104424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin aspart
Description: intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
Study: NCT04261127

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic diagnosis (PMDA panel)
Description: Blood samples for DNA study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Use of RADIAL algorithm
Description: RADIAL card filling (contains clinical and biological data)
Study: NCT05996497

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral measures
Description: behavioral measures

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral measures
Description: behavioral measures

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral measures
Description: behavioral measures

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral measures
Description: behavioral measures

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological measures
Description: Electrophysiological measures

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological measures
Description: Electrophysiological measures

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological measures
Description: Electrophysiological measures

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological measures
Description: Electrophysiological measures

Intervention type: OTHER
Group type: OTHER
Intervention: Training 1
Description: Training 1

Intervention type: OTHER
Group type: OTHER
Intervention: Training 1
Description: Training 1

Intervention type: OTHER
Group type: OTHER
Intervention: Training 1
Description: Training 1

Intervention type: OTHER
Group type: OTHER
Intervention: Training 1
Description: Training 1

Intervention type: OTHER
Group type: OTHER
Intervention: Training 2
Description: Training 2

Intervention type: OTHER
Group type: OTHER
Intervention: Training 2
Description: Training 2

Intervention type: OTHER
Group type: OTHER
Intervention: Training 2
Description: Training 2

Intervention type: OTHER
Group type: OTHER
Intervention: Training 2
Description: Training 2
Study: NCT06065709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness breath awareness meditation
Description: Mindfulness breath awareness meditation
Study: NCT05298293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONCOLAXY Follow-up
Description: The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard.
Study: NCT05654298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Sumatriptan 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Ubrogepant 100 mg
Study: NCT06435806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Illustration design
Description: We will test 10 binary design variants for medical illustrations (for example, with and without cut-away, with and without text labels, etc). Specific variants to be identified during first task of project.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Illustration design
Description: We will test 10 binary design variants for medical illustrations (for example, with and without cut-away, with and without text labels, etc). Specific variants to be identified during first task of project.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Illustration design
Description: We will test 10 binary design variants for medical illustrations (for example, with and without cut-away, with and without text labels, etc). Specific variants to be identified during first task of project.
Study: NCT05903040

Intervention type: DRUG
Intervention: Lasmiditan
Description: Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks

Intervention type: DRUG
Intervention: Lasmiditan
Description: Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks
Study: NCT06176053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homebased stretching exercise and app supervision
Description: The intervention group will perform a self-administered, home-based stretching program (a total of 6 minutes per day) and maintain their daily activities as identified at baseline. Exercises are to be performed daily for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
Study: NCT06168422

Intervention type: DEVICE
Intervention: DES
Description: drug eluting stent

Intervention type: DEVICE
Intervention: DES
Description: drug eluting stent

Intervention type: DEVICE
Intervention: DCB
Description: drug-coated balloon

Intervention type: DEVICE
Intervention: DCB
Description: drug-coated balloon
Study: NCT05550597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl
Description: Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl
Description: Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution